200
Views
3
CrossRef citations to date
0
Altmetric
Review

Safety of non-hormonal medications for managing hot flashes

ORCID Icon, , ORCID Icon, &
Pages 215-221 | Received 01 Apr 2021, Accepted 22 Jul 2021, Published online: 28 Jul 2021

References

  • Marsden J. British menopause society british menopause society consensus statement: the risks and benefits of HRT before and after a breast cancer diagnosis. Post Reprod Health. 2019;25(1):33–37.
  • Monteleone P, Mascagni G, Giannini A, et al. Symptoms of menopause — global prevalence, physiology and implications. Nat Rev Endocrinol. 2018;14(4):199–215. .
  • Ryu KJ, Park H, Park JS, et al. Vasomotor symptoms: more than temporary menopausal symptoms. J Menopausal Med. 2020;26(3):147. .
  • Baber RJ, Panay N, Fenton A. IMS writing group 2016 IMS recommendations on women’s midlife health and menopause hormone therapy. Climacteric 2016;19(2):109–150. .
  • The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of the North American menopause society. Menopause 2017;24:728–753.
  • Cagnacci A, Gambacciani M, Gallo M, et al. Recommendations on menopausal hormone replacement therapy. Minerva Ginecol. 2019; 71(6):395–403.
  • Hodgson SF, Watts NB, Bilezikian JP, et al. American association of clinical endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract. 2003;9(6):544–564.
  • Mosconi P, Donati S, Colombo C, et al. Informing women about hormone replacement therapy: the consensus conference statement. BMC Women’s Health. 2009;9:14.
  • Riemma G, Schiattarella A, La Verde M, et al. Efficacy of low-dose paroxetine for the treatment of hot flushes in surgical and physiological postmenopausal women: systematic review and meta-analysis of randomized trials. Medicina (Kaunas). 2019;55(9):554.
  • Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: an endocrine society scientific statement. J Clin Endocrinol Metab. 2010;95(7_supplement_1):s1–s66.
  • KRONENBERG F. Hot flashes: epidemiology and physiologya. Ann N Y Acad Sci. 1990;592(1):52–86.
  • De Franciscis P, Colacurci N, Riemma G, et al. A nutraceutical approach to menopausal complaints. Medicina (Kaunas). 2019;55(9):544.
  • Ramaa CS, Shirode AR, Mundada AS, et al. Nutraceuticals - an emerging era in the treatment and prevention of cardiovascular diseases. Curr Pharm Biotechnol. 2006;7(1):15–23.
  • Mainini G, Passaro M, Schiattarella A, et al. Prevention and treatment of cystitis during menopause: efficacy of a nutraceutical containing D-mannose, inulin, cranberry, bearberry, Olea europaea, Orthosiphon and Lactobacillus acidophilus. Prz Menopauzalny. 2020;19:130–134.
  • Schiattarella A, Riemma G, La Verde M, et al. Polycystic ovary syndrome and probiotics: a natural approach to an inflammatory disease. Curr Women’s Health Rev. 2021;17(1):14–20.
  • Mahady GB, Parrot J, Lee C, et al. Botanical dietary supplement use in peri- and postmenopausal women. Menopause. 2003;10:65–72.
  • Bedell S, Nachtigall M, Naftolin F. The pros and cons of plant estrogens for menopause. J Steroid Biochem Mol Biol. 2014;139:225–236.
  • Lethaby A, Marjoribanks J, Kronenberg F, et al. Phytoestrogens for menopausal vasomotor symptoms. Cochrane Database Syst Rev. 2013;12:CD001395.
  • Pilšáková L, Riečanský I, Jagla F. The physiological actions of isoflavone phytoestrogens. Physiol Res. 2010;59(5):651–664.
  • Pino AM, Valladares LE, Palma MA, et al. Dietary isoflavones affect sex hormone-binding globulin levels in postmenopausal women. J Clin Endocrinol Metab. 2000;85:2797–2800.
  • Barnes S. The biochemistry, chemistry and physiology of the isoflavones in soybeans and their food products. Lymphat Res Biol. 2010;8(1):89–98.
  • Rowland I, Faughnan M, Hoey L, et al. Bioavailability of phyto-oestrogens. Br J Nutr. 2003;89(S1):S45–S58.
  • De Franciscis P, Grauso F, Luisi A, et al. Adding agnus castus and magnolia to soy isoflavones relieves sleep disturbances besides postmenopausal vasomotor symptoms-long term safety and effectiveness. Nutrients 2017;9(2):129.
  • Gaya P, Medina M, Sánchez-Jiménez A, et al. Phytoestrogen metabolism by adult human gut microbiota. Molecules 2016;21(8):1034.
  • Daily JW, Ko BS, Ryuk J, et al. Equol decreases hot flashes in postmenopausal women: a systematic review and meta-analysis of randomized clinical trials. J Med Food. 2019;22(2):127–139.
  • Murota K, Nakamura Y, Uehara M. Flavonoid metabolism: the interaction of metabolites and gut microbiota. Biosci Biotechnol Biochem. 2018;82(4):600–610.
  • Kanadys W, Barańska A, Błaszczuk A, et al. Evaluation of clinical meaningfulness of red clover (Trifolium pratense L.) extract to relieve hot flushes and menopausal symptoms in peri- and post-menopausal women: a systematic review and meta-analysis of randomized controlled trials. Nutrients 2021 Apr 11;13(4):1258.
  • Lambert MNT, Thorup AC, Hansen ESS, et al. Combined red clover isoflavones and probiotics potently reduce menopausal vasomotor symptoms. PLoS One. 2017 Jun 7;12(6):e0176590.
  • Dietz BM, Hajirahimkhan A, Dunlap TL, et al. Botanicals and their bioactive phytochemicals for women’s health. Pharmacol Rev. 2016;68(4):1026–1073.
  • Burdette JE, Liu J, Chen S, et al. Black Cohosh acts as a mixed competitive ligand and partial agonist of the serotonin receptor. J Agric Food Chem. 2003;51(19):5661–5670.
  • Powell SL, Gödecke T, Nikolic D, et al. In vitro serotonergic activity of black cohosh and identification of N ω-methylserotonin as a potential active constituent. J Agric Food Chem. 2008;56(24):11718–11726.
  • Genazzani A, Panay N, Simoncini T, et al. Purified and specific cytoplasmic pollen extract: a non-hormonal alternative for the treatment of menopausal symptoms. Gynecological Endocrinol. 2020;36(3):190–196.
  • De Franciscis P, Conte A, Schiattarella A, et al. Non-hormonal treatments for menopausal symptoms and sleep disturbances: a comparison between purified pollen extracts and soy isoflavones. Curr Pharm Des. 2020;26(35):4509–4514.
  • Colacurci N, De Franciscis P, Atlante M, et al. Endometrial, breast and liver safety of soy isoflavones plus Lactobacillus sporogenes in post-menopausal women. Gynecological Endocrinol. 2013;29(3):209–212.
  • Ju YH, Doerge DR, Allred KF, et al. Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice. Cancer Res. 2002;62:2474–2477.
  • Ju YH, Doerge DR, Woodling KA, et al. Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo. Carcinogenesis. 2008;29(11):2162–2168.
  • Knight DC, Howes JB, Eden JA, et al. Effects on menopausal symptoms and acceptability of isoflavone-containing soy powder dietary supplementation. Climacteric 2001;4(1):13–18.
  • Levis S, Strickman-Stein N, Ganjei-Azar P, et al. Soy isoflavones in the prevention of menopausal bone loss and menopausal symptoms: a randomized, double-blind trial. Arch Internal Med. 2011;171(15):1363–1369.
  • Tice JA, Ettinger B, Ensrud K, et al. Phytoestrogen supplements for the treatment of hot flashes: the Isoflavone Clover Extract (ICE) Study: a randomized controlled trial. JAMA. 2003;290(2):207–214.
  • Imhof M, Gocan A, Reithmayr F, et al. Effects of a red clover extract (MF11RCE) on endometrium and sex hormones in postmenopausal women. Maturitas 2006;55(1):76–81.
  • Baber RJ, Templeman C, Morton T, et al., Randomized placebo-controlled trial of an isoflavone supplement and menopausal symptoms in women. Climacteric. 2(2): 85–92. 1999.
  • Geller SE, Shulman LP, van Breemen RB, et al., Safety and efficacy of black cohosh and red clover for the management of vasomotor symptoms: a randomized controlled trial. Menopause. 16(6): 1156–1166. 2009.
  • Fritz H, Seely D, Flower G, et al. Soy, red clover, and isoflavones and breast cancer: a systematic review. PLoS One. 2013;8(11):e81968.
  • Zhao TT, Jin F, Li JG, et al., Dietary isoflavones or isoflavone-rich food intake and breast cancer risk: a meta-analysis of prospective cohort studies. Clin Nutr. 38(1): 136–145. 2019.
  • Ilieș M, Uifălean A, Pașca S, et al. From proteomics to personalized medicine: the importance of isoflavone dose and estrogen receptor status in breast cancer cells. J Pers Med. 2020;10.
  • Sim EJ, Ko KP, Ahn C, et al., Isoflavone intake on the risk of overall breast cancer and molecular subtypes in women at high risk for hereditary breast cancer. Breast Cancer Res Treat. 184(2): 615–626. 2020.
  • Wei Y, Lv J, Guo Y, et al. Soy intake and breast cancer risk: a prospective study of 300,000 Chinese women and a dose–response meta-analysis. Eur J Epidemiol. 2020;35(6):567–578.
  • Douglas CC, Johnson SA, Arjmandi BH. Soy and its isoflavones: the truth behind the science in breast cancer. Anti-Cancer Agents in Med Chem. 2013;13(8):1178–1187.
  • Castelo-Branco C, Gambacciani M, Cano A, et al., Review & meta-analysis: isopropanolic black cohosh extract iCR for menopausal symptoms – an update on the evidence. Climacteric. 24(2): 109–119. 2021.
  • Uebelhack R, Blohmer JU, Graubaum HJ, et al. Black cohosh and St. John’s wort for climacteric complaints: a randomized trial. Obstetrics Gynecol. 2006;107(2, Part 1):247–255.
  • Osmers R, Friede M, Liske E, et al. Efficacy and safety of isopropanolic black cohosh extract for climacteric symptoms. Obstetrics Gynecol. 2005;105(5, Part 1):1074–1083.
  • Mahady GB, Dog TL, Barrett ML, et al. United States pharmacopeia review of the black cohosh case reports of hepatotoxicity. Menopause. 2008;15(4):628–638.
  • Naser B, Schnitker J, Minkin MJ, et al. Suspected black cohosh hepatotoxicity. Menopause 2011;18(4):366–375.
  • Lüde S, Török M, Dieterle S, et al. Hepatic effects of Cimicifuga racemosa extract in vivo and in vitro. Cell Mol Life Sci. 2007;64(21):2848–2857.
  • Chen J, Gao H, Li Q, et al. Efficacy and safety of remifemin on peri-menopausal symptoms induced by post-operative GnRH-a therapy for endometriosis: a randomized study versus tibolone. Med Sci Monit. 2014;20:1950–1957.
  • Nappi RE, Malavasi B, Brundu B, et al. Efficacy of Cimicifuga racemosa on climacteric complaints: a randomized study versus low-dose transdermal estradiol. Gynecological Endocrinol. 2005;20(1):30–35.
  • Rostock M, Fischer J, Mumm A, et al. Black cohosh (Cimicifuga racemosa) in tamoxifen-treated breast cancer patients with climacteric complaints – a prospective observational study. Gynecological Endocrinol. 2011;27(10):844–848.
  • Jacobson JS, Troxel AB, Evans J, et al. Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. J clin oncol. 2001;19(10):2739–2745.
  • Henneicke-von Zepelin HH. 60 years of Cimicifuga racemosa medicinal products : clinical research milestones, current study findings and current development. Wiener Medizinische Wochenschrift. 2017;167(7–8):147–159.
  • Jiang K, Jin Y, Huang L, et al. Black cohosh improves objective sleep in postmenopausal women with sleep disturbance. Climacteric 2015;18(4):1950–1957.
  • Lundström E, Hirschberg AL, Söderqvist G. Digitized assessment of mammographic breast density – effects of continuous combined hormone therapy, tibolone and black cohosh compared to placebo. Maturitas 2011;70(4):361–364.
  • Henneicke-von Zepelin HH, Meden H, Kostev K, et al. Isopropanolic black cohosh extract and recurrence-free survival after breast cancer. Int J Clin Pharmacol Ther. 2007;45(3):143–154.
  • Hellström AC, Muntzing J. The pollen extract Femal—a nonestrogenic alternative to hormone therapy in women with menopausal symptoms. Menopause 2012;19(7):30–35.
  • Fait T, Sailer M, Regidor PA. Prospective observational study to evaluate the efficacy and safety of the pollen extract Sérélys® in the management of women with menopausal symptoms. Gynecological Endocrinol. 2019;35(4):360–363.
  • Seeger H, Ruan X, Neubauer H, et al. Membrane-initiated effects of Serelys® on proliferation and apoptosis of human breast cancer cells. Gynecological Endocrinol. 2018;34(4):353–356.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.